Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Targeted siRNA expression plasmid aiming at LRRK2 and application of siRNA expression plasmid in aspect of Parkinson's disease

A gene expression and sequence technology, applied in the application field of the method in the treatment of Parkinson's disease, can solve the problems of high price and trauma of ASO, and achieve the effects of low cost, improvement of abnormal behavior and alleviation of pain.

Pending Publication Date: 2022-04-19
NANJING UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment method of ASO to reduce the level of LRRK2mRNA and inhibit its translation has achieved initial clinical success, but ASO needs to be administered by intrathecal injection, which is somewhat invasive
In addition, ASO is expensive and cannot be afforded by the vast majority of PD patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeted siRNA expression plasmid aiming at LRRK2 and application of siRNA expression plasmid in aspect of Parkinson's disease
  • Targeted siRNA expression plasmid aiming at LRRK2 and application of siRNA expression plasmid in aspect of Parkinson's disease
  • Targeted siRNA expression plasmid aiming at LRRK2 and application of siRNA expression plasmid in aspect of Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 Construction of LRRK2 siRNA / RVG plasmid and detection of interference efficiency

[0014] We used restriction endonucleases to treat the control plasmid, recovered the linear vector, and used T4 ligase to connect the RVG-LRRK2 siRNA combination fragment to the vector; the obtained ligation product was transformed and spread on the resistance plate; The single clone was picked two days later and sequenced to confirm the correctness of the plasmid sequence. According to this method, three combined fragments containing different LRRK2 were ligated into the vector to form plasmid molecules, which were named LRRK2si-1, LRRK2si-2, and LRRK2si-3.

[0015] The three kinds of plasmid molecules were respectively transfected into the human neural cell line SHSY5Y with a confluence of 60-70%, and the expression level of LRRK2 in the cells was detected by western experiment after 48 hours. The results showed that the two LRRK2 siRNAs had relatively high interference effic...

Embodiment 2

[0016] Example 2 Inhibitory effect of plasmid-expressed siRNA on LRRK2 in vivo

[0017] LRRK2 si-1 and LRRK2si-2 were used for subsequent experiments, and the control plasmid and LRRK2siRNA / RVG plasmid were injected into the tail vein of 3-month-old PD transgenic mice R1441G at a dose of 10 mg / kg, once every two days, for a total of After 7 injections, the mice were sacrificed 24 hours after the last injection, and the brain tissues of the mice were taken for western blot experiments. The results showed that both plasmid molecules could effectively reduce the expression level of LRRK2 in brain tissue in vivo, and the interference efficiency of LRRK2si-2 was higher.

[0018] The 8-week-old PD transgenic mice R1441G were randomly divided into control group and treatment group, and the control plasmid and LRRK2si-2 plasmid were injected into the tail vein of the R1441G mice at a dose of 10 mg / kg, once every two days, and a total of 7 injections , the mice were sacrificed 24 hour...

Embodiment 3

[0019] Example 3 Effect of LRRK2 siRNA / RVG plasmid on exercise ability of PD transgenic mice

[0020] At the same time, we also evaluated the exercise ability of PD transgenic mice. Before administration, we performed fatigue rotarod test and balance experiment on R1441G mice, trained for one day, and then three times a day for a total of three days. Three days of fatigue rotating rod test and pole climbing test. The results showed that the injection of LRRK2 siRNA / RVG plasmid could effectively alleviate the fatigue rotarod test and the deterioration of pole climbing indicators in R1441G mice.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a targeted siRNA (small interfering Ribonucleic Acid) expression plasmid for inhibiting an LRRK2 gene. According to the expression plasmid, rabies virus glycoprotein (RVG) and siRNA aiming at the LRRK2 gene are subjected to combined expression. After the plasmid is subjected to caudal vein injection, the gene expression level in brain tissues is reduced; related inflammations are relieved; when the plasmid is intravenously injected into the tail of a PD transgenic mouse for a period of time, the deterioration of fatigue bar rotation and pole climbing experiment indexes of the mouse can be effectively relieved, namely, the dyskinesia of the mouse is relieved.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to the self-assembly expression in vivo of a combination of nervous system targeting peptides and siRNA against LRRK2, and the application of the method in the treatment of Parkinson's disease. Background technique [0002] Parkinson's disease (PD), one of the major neurodegenerative diseases causing movement disorders, is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, associated with α-synuclein and other proteins (Lewy bodies and Lewy associated with the formation of fibrous aggregates composed of neurites). The main clinical manifestations are an asymmetric onset of symptoms (Parkinson's usually begins on one side of the body); resting tremor is present. If left untreated, symptoms can lead to disability, severe immobility, and falls and progressively worsen [1] . Therefore, it is very important to find safe and effective treatment methods. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K31/713A61P25/16
CPCC12N15/1137A61K31/713A61P25/16C12N2310/141
Inventor 单扬扬陈熹
Owner NANJING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com